World-class experts.

Driving our success in this program is our team of world-class experts with extensive Pharma experience in kinase inhibitor discovery and development.

Image Link
Novel kinase inhibitors.

Confluence Life Science's kinase inhibitors target key signal transduction enzymes involved in the regulation of cancer growth and survival, or in the modulation of chronic inflammation.

Image Link
Demonstrated success.

Our team has documented scientific excellence with an impressive publication list of over 200 peer reviewed manuscripts and over 90 issued patents. We have led and carried out research leading to identification of 21 clinical candidates, with 13 advancing to Phase 2 clinical studies and 4 to marketed drugs.

Image Link

Discovering and developing new drugs for human disease.

Confluence Life Sciences (CLS) is developing innovative treatments for human and animal diseases with a pipeline of programs based on novel kinase targets and novel approaches to challenging kinase targets. These drugs are designed to target the large unmet medical needs associated with cancer and chronic inflammatory and autoimmune disease.